{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]}],"title":"Stable Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}],"title":"Partial Response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"5"}],"units":"Participants"}],"description":"Best Overall Response (BOR): best response recorded from start of study treatment until disease progression (PD) or recurrence based on response evaluation criteria in solid tumors (RECIST) version 1.1 for target and non-target lesions. Participants with evaluable disease were also eligible for assessment.","groups":[{"description":"Participants received eribulin mesylate 1.1 mg/m\\^2, intravenously over 2 to 5 minutes on Days 1 and 8 of each 21-day treatment cycle for up to 4 cycles, or until PD or unacceptable toxicity or DLT's.","id":"OG000","title":"Part A1: Eribulin Mesylate 1.1 mg/m^2"},{"description":"Participants received eribulin mesylate 1.4 mg/m\\^2, intravenously over 2 to 5 minutes on Days 1 and 8 of each 21-day treatment cycle for up to 8 cycles, or until PD or unacceptable toxicity or drug related DLT's.","id":"OG001","title":"Part A1: Eribulin Mesylate 1.4 mg/m^2"},{"description":"Participants received eribulin mesylate 1.8 mg/m\\^2, intravenously over 2 to 5 minutes on Days 1 and 8 of each 21-day treatment cycle for up to 5 cycles, or until PD or unacceptable toxicity or drug related DLT's.","id":"OG002","title":"Part A1: Eribulin Mesylate 1.8 mg/m2"},{"description":"Participants received eribulin mesylate 1.4 mg/m\\^2, intravenously over 2 to 5 minutes on Days 1 and 8 of each 21-day treatment cycle for up to 2 cycles, or until PD or unacceptable toxicity or drug related DLT's for evaluation of PK.","id":"OG003","title":"Part A1: Eribulin Mesylate PK Expansion"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The SAS included all participants who received at least one dose of study drug.","reportingStatus":"POSTED","timeFrame":"First dose of study drug (Baseline) up to approximately Cycle 8 (21-days treatment cycle)","title":"Number of Participants With Best Overall Response","type":"SECONDARY","unitOfMeasure":"Participants"}